Michael Steinman, MD, professor of medicine, University of California, San Diego, discusses effective strategies for improving medication management for patients and how these strategies can improve outcomes, such as medication adherence.
Michael Steinman, MD, professor of medicine, University of California, San Diego, discusses effective strategies for improving medication management for patients and how these strategies can improve outcomes, such as medication adherence.
Transcript
What are some strategies that can effectively improve medication management for patients?
There’s a lot of different strategies that can improve medication management, and I think one of the key things is that there’s a huge spectrum. So, one of the challenges is that patients need education, so some strategies can improve education. There’s some strategies of care coordination between physicians, there’s issues of prescribing inappropriate or appropriate medications and how can we disincentivize the inappropriate ones and incentivize the appropriate ones through a systems approach. There’s issues of patient engagement and empowerment, so there’s this huge gamut of issues, and it’s unlikely that any single intervention will affect all of them, but I think the mistake we sometimes make is focusing on just 1 and ignoring the others because it’s only attacking one small piece of the puzzle, and it’s really kind of helping with multiple different elements and having them all line up that’s ultimately going to make the biggest difference. We can’t do it all at once, but we should keep in mind the big picture even while we’re trying to slice off one particular part.
How do these management strategies improve outcomes like medication adherence and, in turn, improve patient outcomes?
The ultimate goal, of course, is improving patient outcomes, and in some cases that could be getting patients to adhere better to their medications, which are helpful and indicated for them. In some cases, it could be getting patients to stop adhering to their medications, stopping medications that are harmful or unnecessary for them. So, it’s really right sizing the medications, and so part of the strategy is really understanding, first of all, where patients are at, what they’re taking, how adherent they are, why they might be adherent or not adherent, what are some of the barriers and facilitators, and addressing those.
And again, it gets back to the issue of being smart about it. So, we shouldn’t be promoting adherence to medications which really are note necessary or may be excessively costly when there’s a cheaper and maybe easier to take alternative. At the same time, we should be thinking about increasing understanding of patients’ experience of medications and the reasons they’re really taking them so we can stop or avoid medications which aren’t necessary. Particularly for older adults, overuse of medication is very common, and we could probably improve outcomes a lot by stopping those meds.
One final point is that we should really be thinking about outcomes in terms of patient-centered outcomes. Hemoglobin A1c is not an outcome. Blood pressure is not an outcome. Strokes, quality of life, death, things like that, those are the outcomes we should be keeping our eyes on.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More